Skip to main content

Strategies to Increase the Oral Bioavailability of Nucleoside Analogs

Buy Article:

$55.00 plus tax (Refund Policy)

Nucleoside analogs are first line chemotherapy in various severe diseases: AIDS (acquired immunodeficiency disease syndrome), cytomegalovirus infections, cancer etc. However, most of these compounds suffer from poor bioavailability via oral route. In order to get around this drawback, researchers have imagined many strategies including drug metabolism inhibitors, bio adhesive nanoparticles, amino ester prodrugs, as well as enhancing absorption by increasing drug lipophilicity. This paper illustrated these approaches by developing their application to some nucleoside analogs. Moreover, some of these strategies were very successful and some resulting compounds are now approved by FDA (Food and Drug Administration).
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Nucleoside analogs; oral absorption; prodrug

Document Type: Research Article

Affiliations: Univ Paris-Sud, UMR 8612, IFR 141, F-92296 Ch√Ętenay-Malabry, CNRS, UMR 8612, IFR 141, F-92296 Ch√Ętenay-Malabry, France.

Publication date: 2009-04-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more